An open-label trial of memantine for the treatment of posttraumatic stress disorder

An open-label trial of memantine for the treatment of posttraumatic stress disorder - An open-label trial of memantine for PTSD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022467

Enrollment

Registered

2016-05-27

Start date

2016-05-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

posttraumatic stress disorder

Interventions

Memantine intake for 12 weeks (titrated by 5mg/day weekly to the maintenance dose of 20mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with posttraumatic stress disorder (2) Individuals who can understand the nature of this study and provide informed consent

Exclusion criteria

Exclusion criteria: (1) Patients with duration of illness less than 6 months (2) Individuals who received specific psychotherapy (e.g., prolonged exposure therapy, cognitive processing therapy, and eye movement desensitization and reprocessing therapy) within 3 months prior to the recruitment into the study (3) Patients with comorbid schizophrenia, severe manic phase of bipolar disorder, or intellectual disability (4) Individuals with serious suicidal ideation (5) Individuals with severe physical illnesses that can interfere with study participation (6) Pregnant women (7) Individuals with the following physical conditions that are described in manufacturer's package insert as "careful administration": -History of epilepsy or convulsion -Renal dysfunction -Factors increasing urine pH -Severe liver dysfunction (8) Patients considered unqualified for the study by their attending physicians

Design outcomes

Primary

Measure	Time frame
(1) PTSD diagnosis/severity (PTSD Diagnostic Scale: PDS)	—

Secondary

Measure	Time frame
(1) PTSD severity (Impact of Event Scale-Revised: IES-R) (2) Cognitive function (Repeatable Battery for the Assessment of Neuropsychological Status: RBANS) (3) Depressive symptoms (Beck Depression Inventory-II) (4) Anxiety symptoms (State-Trait Anxiety Inventory) (5) Cognitive changes after traumatic events (Posttraumatic Cognitions Inventory) (6) Overall symptom severity/improvement (Clinical Global Impression) (7) Adverse events (UKU Side-Effect Rating Scale)	—

Measure

Time frame

(1) PTSD severity (Impact of Event Scale-Revised: IES-R) (2) Cognitive function (Repeatable Battery for the Assessment of Neuropsychological Status: RBANS) (3) Depressive symptoms (Beck Depression Inventory-II) (4) Anxiety symptoms (State-Trait Anxiety Inventory) (5) Cognitive changes after traumatic events (Posttraumatic Cognitions Inventory) (6) Overall symptom severity/improvement (Clinical Global Impression) (7) Adverse events (UKU Side-Effect Rating Scale)

—

Countries

Japan

Contacts

Public ContactHiroaki Hori

National Institute of Mental Health, National Center of Neurology and Psychiatry Department of Behavioral Medicine

hori@ncnp.go.jp042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026